Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pisano

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Molecular Pharmacology|November 28, 2000
Replacement of an NH(3) by an iminoether in transplatin makes an antitumor drug from an inactive compoundM Leng, D Locker, M J Giraud-Panis, et al.
Digestive Diseases and Sciences|April 29, 1999
Gastrosparing effect of new antiinflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxideC Pisano, D Grandi, G Morini, et al.
Pathophysiology of Haemostasis and Thrombosis|September 5, 2003
Involvement of heparanase in tumor progression and normal differentiationI Vlodavsky, E Zcharia, O Goldshmidt, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.
Urologic Oncology|November 18, 2015
The effect of broader, directed antimicrobial prophylaxis including fungal coverage on perioperative infectious complications after radical cystectomyJoseph J Pariser, Blake B Anderson, Shane M Pearce, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancerR Tambaro, S Greggi, R V Iaffaioli, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 13, 2018
Trabectedin in Ovarian Cancer: is it now a Standard of Care?J Ventriglia, I Paciolla, S C Cecere, et al.
British Journal of Cancer|January 14, 2012
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trialJ Alexandre, C Brown, D Coeffic, et al.
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Molecular Pharmacology|November 28, 2000
Replacement of an NH(3) by an iminoether in transplatin makes an antitumor drug from an inactive compoundM Leng, D Locker, M J Giraud-Panis, et al.
Digestive Diseases and Sciences|April 29, 1999
Gastrosparing effect of new antiinflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxideC Pisano, D Grandi, G Morini, et al.
Pathophysiology of Haemostasis and Thrombosis|September 5, 2003
Involvement of heparanase in tumor progression and normal differentiationI Vlodavsky, E Zcharia, O Goldshmidt, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.
Urologic Oncology|November 18, 2015
The effect of broader, directed antimicrobial prophylaxis including fungal coverage on perioperative infectious complications after radical cystectomyJoseph J Pariser, Blake B Anderson, Shane M Pearce, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancerR Tambaro, S Greggi, R V Iaffaioli, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 13, 2018
Trabectedin in Ovarian Cancer: is it now a Standard of Care?J Ventriglia, I Paciolla, S C Cecere, et al.
British Journal of Cancer|January 14, 2012
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trialJ Alexandre, C Brown, D Coeffic, et al.
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
Pageof 8